Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation

NCT02417207 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis B
Liver Transplantation

Interventions

DRUG: Entecavir combined long-term low-dose HBIG group intramuscular
DRUG: Entecavir combined HBIG group short-term high-dose intravenous

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University